William Blair Initiates Coverage on Revolution Medicines With $226 Target
William Blair initiated coverage on Revolution Medicines, Inc. (NASDAQ:RVMD) with an Outperform rating and a $226 price forecast. The endorsement comes as European regulators recommended approving Rasonque (daraxonrasib) for patients with metastatic pancreatic cancer who have already received at least one prior systemic therapy. The drug previously received U.S. regulatory approval in August as a first-in-class targeted RAS(ON) inhibitor.
Analyst Alethia Young cited years of research into RAS biology as a major driver for the biotechnology firm's growth potential. While Rasonque is already seeing rapid adoption in pancreatic cancer treatments, the analyst expects the company to expand its therapy pipeline into other oncology areas, including lung cancer. Young projects $9.8 billion in annual revenue by 2032 based on current and expanding treatments.
Investors should monitor upcoming clinical trial developments over the next year. Results from the RASolve 301 phase trial evaluating daraxonrasib in previously treated lung cancer patients are anticipated in 2027. Additionally, Revolution Medicines plans to present further clinical data and outline its broader development strategy for colorectal cancer treatments during the fourth quarter of 2026.
Key points
- William Blair initiated coverage on Revolution Medicines, Inc. (NASDAQ:RVMD) with an Outperform rating and a $226 price target.
- European regulators recommended approval for Rasonque to treat metastatic pancreatic cancer in patients who received prior therapy.
- The U.S. FDA approved Rasonque in August as the first targeted cancer therapy in the RAS(ON) inhibitor class.
- Analyst Alethia Young forecasts $9.8 billion in company revenue by 2032 from pancreatic and lung cancer treatments.
- Revolution Medicines expects to share additional clinical trial data and strategic updates for colorectal cancer in late 2026.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is William Blair's rating and price target for Revolution Medicines?
William Blair initiated coverage on Revolution Medicines with an Outperform rating and a $226 price forecast, citing strong growth prospects in its cancer drug pipeline.
Has Rasonque been approved for treating pancreatic cancer?
Yes, the U.S. FDA approved Rasonque in August for metastatic pancreatic cancer, and European regulatory advisers recommended its approval for patients who received at least one prior systemic therapy.
What upcoming catalysts should Revolution Medicines investors watch for?
Investors should watch for additional data and a colorectal cancer strategy update in the fourth quarter of 2026, as well as results from the RASolve 301 lung cancer trial expected in 2027.